News >

MRD Prognostic of Poorer Outcomes in AML

Jason Harris
Published: Monday, Apr 02, 2018

blood cells Molecular minimal residual disease (MRD) was associated with a higher rate of relapse and a lower rate of relapse-free survival (RFS) and overall survival (OS) for patients with newly-diagnosed acute myeloid leukemia (AML), according to findings published in the New England Journal of Medicine. 

= .003). There were no significant interactions observed between the detection of residual disease and the other prognostic factors in the multivariate model, type of consolidation therapy, or disease entity (AML vs. refractory anemia with excess of blasts).
Jongen-Lavrencic M, Grob T, Hanekamp K, et al. Molecular minimal residual disease in acute myeloid leukemia [published online March 29, 2018]. N Engl J Med. 2018; 378:1189-1199. doi: 10.1056/NEJMoa1716863.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication